• PDF / 169,839 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 70 Downloads / 162 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 3 case reports In a prospective study of 36 patients, who had chronic hepatitis B (CHB) and who were treated between 2012 and 2017 in Serbia, 3 adult patients [sexes and exact ages not stated] were described, who developed ovarian cancer, depression, debilitating myalgia, arthralgia, neutropenia or thyroiditis during treatment with peginterferon-alfa-2a for CHB [not all durations of treatments to reactions onsets and outcomes not stated]. The patients, who had CHB, were divided into two groups (HBeAg+) and (HBeAg-). Subsequently, patients started on SC peginterferon-alfa-2a 180µg once a week for 48 weeks. However, two patients developed neutropenia (1 patient) and thyroiditis (1 patient). The remaining patient, who had an early virological response, developed debilitating myalgia and arthralgia. The same patient also developed ovarian cancer during the month 4 of the treatment and a severe form of depression during month 32 of the treatment. The patient with neutropenia had a reduction of peginterferon-alfa-2a dosage. Treatment with peginterferon-alfa-2a was stopped for one patient, who had debilitating myalgia, arthralgia, ovarian cancer and depression. One patient had complete resolution of thyroiditis and completed full treatment with peginterferon-alfa-2a. Bojovic K, et al. Efficacy and safety of pegylated-interferon alpha therapy in patients with chronic hepatitis B in recource-limited settings: A Serbian single-center experience. 803514572 Vojnosanitetski Pregled. Military-Medical and Pharmaceutical Review 77: 796-803, No. 8, 2020. Available from: URL: http://doi.org/10.2298/VSP180727150B

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830